3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 3
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
187
Neoplasm Metastasis
150
Neoplasms
141
Leukemia, Myeloid, Acute
138
Colorectal Neoplasms
131
Breast Neoplasms
120
Melanoma
95
Ovarian Neoplasms
93
Prostatic Neoplasms
89
Recurrence
85
Multiple Myeloma
83
Lung Neoplasms
78
Pancreatic Neoplasms
77
Glioblastoma
77
Squamous Cell Carcinoma of Head and Neck
75
Myelodysplastic Syndromes
66
Lymphoma, Non-Hodgkin
65
Triple Negative Breast Neoplasms
57
Glioma
57
Stomach Neoplasms
54
Endometrial Neoplasms
51
Precursor Cell Lymphoblastic Leukemia-Lymphoma
50
Carcinoma, Renal Cell
49
Brain Neoplasms
48
Small Cell Lung Carcinoma
47
Lymphoma, Large B-Cell, Diffuse
45
Carcinoma, Hepatocellular
45
Lymphoma, B-Cell
42
Lymphoma, Follicular
40
Advanced Solid Tumors
40
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Male Urogenital Diseases
×
90 days
×
Clear all
NCT07103018
2026-03-23
STRIKE-001
K36 Therapeutics, Inc.
Phase 1
Recruiting
144 enrolled